Hexedrone
![]() | |
Names | |
---|---|
IUPAC name 2-(Methylamino)-1-phenylhexan-1-one | |
Other names Hexedrone, HEX | |
Identifiers | |
3D model (JSmol) | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C13H18NO | |
Molar mass | 204.293 g·mol−1 |
Appearance | White crystalline solid |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Hexadrone is a stimulant of the substituted cathinone class which has been sold as a designer drug.[1] Through analysis of the Structure-Activity Relationships in similar cathinones such as MDPV, hexedrone is believed to be a norepinephrine–dopamine reuptake inhibitor.
Subjective effects include stimulation, disinhibition, thought acceleration and euphoria.
Little is known about toxicity, addiction, and abuse potential of hexedrone. Due to its novelty and extremely short history of human usage, all information related to the use of this compound should be treated with caution.
Legal status
[edit]In the UK, Hexedrone is a Class B drug under The Misuse of Drugs Act 1971 (Amendment) Order 2010 following the ACMD's report on substituted cathinone derivatives,[2] making it illegal to sell, buy, or possess without a license.[3][4]
See also
[edit]References
[edit]- ^ Błażewicz, A., Bednarek, E., Sitkowski, J. et al. Identification and structural characterization of four novel synthetic cathinones: α-methylaminohexanophenone (hexedrone, HEX), 4-bromoethcathinone (4-BEC), 4-chloro-α-pyrrolidinopropiophenone (4-Cl-PPP), and 4-bromo-α-pyrrolidinopentiophenone (4-Br-PVP) after their seizures. Forensic Toxicol 2017; 35: 317–332. doi:10.1007/s11419-017-0360-2
- ^ "ACMD Consideration of The Cathinones". ACMD. 31 March 2010.
- ^ "A change to the Misuse of Drugs Act 1971 : Control of mephedrone and other cathinone derivatives". Home Office. 16 April 2010. Archived from the original on 25 January 2013.
{{cite web}}
: CS1 maint: bot: original URL status unknown (link) - ^ "The Misuse of Drugs Act 1971 (Amendment) Order 2010". Home Office. 12 April 2010.